Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmmerson Regulatory News (EML)

Share Price Information for Emmerson (EML)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.95
Bid: 1.90
Ask: 2.00
Change: 0.00 (0.00%)
Spread: 0.10 (5.263%)
Open: 1.95
High: 1.95
Low: 1.95
Prev. Close: 1.95
EML Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hardman & Co Research: Emmerson Plc (EML): A competitively well-placed potash play

18 May 2021 13:15

Hardman & Co Research Hardman & Co Research: Emmerson Plc (EML): A competitively well-placed potash play 18-May-2021 / 13:15 GMT/BST


May 2021 Hardman & Co Investor Forum company research:

Emmerson Plc (EML)

On 12 May we were delighted to host our fourth virtual Investor Forum. During the forum, CEO Graham Clarke of Emmerson Plc discussed the company's strategic value, framing it in the context of the other global potash companies, as well as the broader fertiliser producer market. He went on to describe the strong political relationships the company has in Morocco and how the project funding has progressed with strategic partners.

We would like to share with you the research note & slide pack, along with the recording of the presentation:

Read Emmerson research note | Download Emmerson slide pack |

Watch Emmerson forum recording

If you are interested in meeting the company, you can register your interest by clicking here.

To contact us:

Hardman & Co1 Frederick's Place

London

EC2R 8AE

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Paul Singer

+44 20 3693 7075

 

ps@hardmanandco.com 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1197880 18-May-2021 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
31st May 202410:56 amRNSGrant of Share Options and PDMR dealing
31st May 20247:00 amRNSNotice of AGM and Posting of Annual Report
24th May 20247:00 amRNS2023 Financial Results
22nd Apr 202411:47 amRNSTR-1: Notification of major holdings
8th Apr 20244:45 pmRNSResults of Oversubscribed REX Retail Offer
8th Apr 20247:01 amRNSREX Retail Offer
8th Apr 20247:00 amRNSQ1 Update, Equity Placing and Retail Offer
11th Mar 20247:00 amRNSCommittee Upholds Environmental Approval Referral
1st Feb 20247:00 amRNSScoping Study on Breakthrough New Processing Route
8th Jan 20247:00 amRNSQ4 Update
21st Dec 20237:00 amRNSExtension of Mandated Lead Arrangers
26th Sep 20237:00 amRNSInterim Results for the six months to 30 June 2023
21st Sep 20237:00 amRNSQ3 2023 and Financing update
11th Sep 202311:38 amRNSMorocco Statement
11th Jul 202311:57 amRNSDirector/PDMR Shareholding
10th Jul 20234:30 pmRNSDirector/PDMR Shareholding
6th Jul 20232:49 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSQ2 Update
6th Jun 20237:00 amRNSExercise & Allotment of Shares
31st May 202312:01 pmRNSResult of AGM
5th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
13th Apr 20237:00 amRNS2022 Financial Results and Q1 Update
14th Feb 20237:00 amRNSMandated Lead Arrangers Appointed for Financing
9th Jan 20237:00 amRNSQ4 Update
3rd Jan 20237:00 amRNSAppointment of Liberum as Nominated Advisor
21st Nov 20227:00 amRNSPotash and Salt Offtake MOUs
27th Sep 20227:00 amRNSDirector/PDMR Shareholding
26th Sep 20221:45 pmRNSResults of REX Retail Offer & Total Voting Rights
26th Sep 20227:02 amRNSREX Retail Offer
26th Sep 20227:01 amRNSRenewal of Strategic Investment & Equity Placing
26th Sep 20227:00 amRNSInterim Results for the six months to 30 June 2022
16th Aug 20224:18 pmRNSExercise of Options & Director/PDMR Shareholding
22nd Jul 20229:00 amRNSShare Options Scheme & Director Shareholdings
19th Jul 20225:05 pmRNSReplacement: Director/PDMR Shareholding
18th Jul 20224:00 pmRNSDirector/PDMR Shareholding
11th Jul 20227:00 amRNSQ2 Activities Update
7th Jul 202212:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSExercise of Warrants and Issue of Shares
13th Jun 20227:00 amRNSNotice of AGM and Posting of Annual Report
31st May 20227:00 amRNSAudited Results for the year ended 31 Dec 2021
31st Mar 20227:00 amRNSQ1 Activities Update
15th Mar 20227:00 amRNSGrant of Share Options
21st Feb 20227:00 amRNSAppointment of Chief Financial Officer
16th Feb 20227:00 amRNSAppointment of Corporate Broker
27th Jan 20227:00 amRNSBasic Engineering Packages Awarded to Reminex S.A
25th Jan 20221:00 pmRNSPart Exercise of Options and Issue of Shares
31st Dec 20217:00 amRNSEnd of Year Newsletter
6th Dec 202112:45 pmRNSResult of AGM
6th Dec 202112:31 pmRNSResult of General Meeting
2nd Dec 20217:00 amRNSOperational Update: Khemisset Potash Project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.